Pathogenic role of a protein complex of liver origin as regulator of a proinflammatory program that drives hepatic and intestinal injury in alcoholic liver disease
肝脏来源的蛋白质复合物作为促炎程序的调节剂的致病作用,该程序驱动酒精性肝病中的肝脏和肠道损伤
基本信息
- 批准号:10663785
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAcute Alcoholic HepatitisAffectAffinityAlcoholic Liver DiseasesAntibodiesBindingBiological AssayBiological MarkersCCL2 geneCX3CL1 geneClinicalClinical TrialsComplexDataDiseaseEpithelial CellsEthanolFeedbackFunctional disorderGoalsHMGB1 geneHepaticHepatocyteInfiltrationInflammationInflammatoryInjuryInterleukin-1 betaIntestinal permeabilityKupffer CellsLigandsLiverMacrophageMeasuresMolecularMusMyeloid CellsPathogenesisPathogenicityPathologicPatientsPatternPhosphoproteinsPrediction of Response to TherapyProductionRoleSamplingSerumSignal TransductionSourceSterilityTNF geneTestingTherapeuticTight JunctionsTreatment outcomeVeteransWorkcytokinedesignfeedingin vitro testingin vivointestinal barrierintestinal epitheliumintestinal injuryliver injurynovelnovel therapeuticsoxidationpreventproblem drinkerprogramsprogression riskprotein complexprotein expressionreceptorreceptor bindingreceptor for advanced glycation endproductsresponse
项目摘要
ABSTRACT
Inflammation is a hallmark of alcohol-induced liver injury. Numerous studies established the role of the gut-to-
liver axis, but there is limited information on how the liver-to-gut axis contributes to inflammation and injury in
alcoholic liver disease. It is unknown whether ethanol-induced sterile damage-associated molecular patterns of
liver origin activate a proinflammatory program that, besides being detrimental to the liver, drive intestinal
barrier dysfunction, hence creating an amplifying proinflammatory feedback loop in alcoholic liver disease. Our
overarching goal is to dissect the pathogenic role of a protein complex of liver origin in regulating a
proinflammatory program that drives hepatic and intestinal injury in alcoholic liver disease.
In prior work, we demonstrated that high-mobility group box-1 (HMGB1) is a damage-associated molecular
pattern up-regulated in response to liver injury and participates in the pathogenesis of alcoholic liver disease.
Interestingly, HMGB1 undergoes oxidation only in hepatocytes, and serum levels of oxidized HMGB1
([O]HMGB1) are increased in alcoholic patients. Our preliminary data demonstrate that blocking the production
of [O]HMGB1 in hepatocytes or ablating an HMGB1 receptor (the receptor for advanced glycation end-
products, RAGE) in myeloid cells prevents inflammation, hepatic injury, intestinal barrier dysfunction and
alcoholic liver disease. We show that Kupffer cells and infiltrated macrophages are the main hepatic source of
IL1β. Importantly, we reveal that [O]HMGB1 forms a complex with IL1β. This complex binds RAGE in Kupffer
cells and macrophages to produce a proinflammatory program and increases gut permeability in alcoholic liver
disease.
These encouraging data suggest that a proinflammatory feedback loop initiated by this complex, could
exacerbate hepatic and intestinal injury in alcoholic liver disease. However, key mechanistic aspects of how
this complex promotes the pathogenesis of alcoholic liver disease remain to be elucidated: 1) whether this
complex is of liver origin; 2) whether it is a ligand for RAGE; 3) the signals this complex conveys in Kupffer
cells and macrophages to induce a proinflammatory program that exacerbates hepatic injury; 4) whether it
alters tight junction protein expression in intestinal epithelial cells and increases intestinal barrier dysfunction;
and 5) whether the proinflammatory program itself also contributes to intestinal barrier dysfunction.
We propose a conceptually novel framework of a liver-to-gut proinflammatory feedback loop in alcoholic liver
disease. Our central hypothesis is that this complex is of liver origin and binds RAGE in Kupffer cells and
macrophages to induce a proinflammatory program that exacerbates hepatic injury. By binding RAGE in
intestinal epithelial cells and/or by inducing the proinflammatory program, this complex alters tight junction
protein expression and increases intestinal barrier dysfunction. We will test this hypothesis by pursuing three
specific aims. In Aim 1, we will identify the complex as being of liver origin. In Aim 2, we will determine the
complex binding affinity for RAGE in Kupffer cells and macrophages and identify the signals through which the
complex induces a proinflammatory program that exacerbates hepatic injury. In Aim 3, we will determine if the
complex alters tight junction protein expression and increases intestinal barrier dysfunction by binding RAGE in
intestinal epithelial cells and/or by inducing the proinflammatory program. Therefore, targeting this complex
could have significant therapeutic potential.
抽象的
炎症是酒精引起的肝损伤的一个标志,大量研究证实了肠道对肝损伤的作用。
肝轴,但关于肝肠轴如何导致炎症和损伤的信息有限
酒精性肝病是否与乙醇引起的无菌损伤相关的分子模式尚不清楚。
肝脏来源激活促炎程序,除了对肝脏造成疼痛外,还会驱动肠道
屏障功能障碍,从而在酒精疾病中形成放大的肝脏促炎症反馈回路。
总体目标是剖析肝脏来源的蛋白质复合物在调节
促炎症程序可导致酒精性肝病中的肝脏和肠道损伤。
在之前的工作中,我们证明了高迁移率族盒-1(HMGB1)是一种损伤相关分子
模式因肝损伤而上调,并参与酒精性肝病的发病机制。
HMGB1 仅在肝细胞中发生氧化,氧化 HMGB1 的血清水平
我们的初步数据表明,([O]HMGB1) 在酒精患者中增加。
肝细胞中的 [O]HMGB1 或消除 HMGB1 受体(晚期糖基化末端受体)
产品(RAGE)在骨髓细胞中可预防炎症、肝损伤、肠道屏障功能障碍和
我们发现库普弗细胞和浸润性巨噬细胞是酒精性肝病的主要肝脏来源。
重要的是,我们发现 [O]HMGB1 与 IL1β 形成复合物,该复合物与 Kupffer 中的 RAGE 结合。
细胞和巨噬细胞产生促炎程序并增加酒精肝中的肠道通透性
疾病。
这些令人鼓舞的数据表明,由这种复合物引发的促炎症反馈循环可以
然而,酒精性肝病的关键机制如何加剧肝脏和肠道损伤。
这种复合物促进酒精性肝病的发病机制仍有待阐明:1)这是否
复合物源自肝脏;2) 是否是 RAGE 的配体;3) 该复合物在 Kupffer 中传递的信号
细胞和巨噬细胞诱导促炎程序,加剧肝损伤;4) 是否
改变肠上皮细胞中紧密连接蛋白的表达并增加肠屏障功能障碍;
5)促炎程序本身是否也会导致肠道屏障功能障碍。
我们提出了酒精肝中肝到肠促炎反馈环的概念新颖的框架
我们的中心假设是,该复合物源自肝脏并与库普弗细胞中的 RAGE 结合,并与 RAGE 结合。
巨噬细胞通过结合 RAGE 来诱导促炎程序,从而加剧肝损伤。
肠上皮细胞和/或通过诱导促炎程序,该复合物改变紧密连接
蛋白质表达并增加肠道屏障功能障碍我们将通过三个方面来检验这一假设。
在目标 1 中,我们将确定该复合物是肝脏来源的。在目标 2 中,我们将确定该复合物。
库普弗细胞和巨噬细胞中 RAGE 的复杂结合亲和力,并识别信号
在目标 3 中,我们将确定该复合物是否会诱发促炎程序,从而加剧肝损伤。
复合物通过与 RAGE 结合改变紧密连接蛋白表达并增加肠道屏障功能障碍
肠上皮细胞和/或通过诱导促炎程序因此,针对该复合物。
可能具有显着的治疗潜力。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ablation of high-mobility group box-1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling-deficient mice.
在 Hippo 信号传导缺陷的小鼠中,肝脏中高迁移率组 box-1 的消融可减少肝细胞癌,但会导致高胆红素血症。
- DOI:
- 发表时间:2022-08
- 期刊:
- 影响因子:5.1
- 作者:Athavale, Dipti;Song, Zhuolun;Desert, Romain;Han, Hui;Das, Sukanta;Ge, Xiaodong;Komakula, Sai Santosh Babu;Chen, Wei;Gao, Shenglan;Lantvit, Daniel;Guzman, Grace;Nieto, Natalia
- 通讯作者:Nieto, Natalia
Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
氧化还原敏感的高迁移率 group-1 亚型有助于小鼠肝纤维化的进展和消退。
- DOI:
- 发表时间:2024-03
- 期刊:
- 影响因子:25.7
- 作者:Ge, Xiaodong;Desert, Romain;Magdaleno, Fernando;Han, Hui;Song, Zhuolun;Das, Sukanta;Athavale, Dipti;Chen, Wei;Barahona, Ines;Lantvit, Daniel;Chen, Hui;Hwang, Sunil;Nieto, Natalia
- 通讯作者:Nieto, Natalia
Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
基于基质体基因的肝纤维化患者亚分类可识别临床和分子异质性。
- DOI:
- 发表时间:2023-10-01
- 期刊:
- 影响因子:0
- 作者:Chen, Wei;Sun, Yameng;Chen, Shuyan;Ge, Xiaodong;Zhang, Wen;Zhang, Ning;Wu, Xiaoning;Song, Zhuolun;Han, Hui;Desert, Romain;Yan, Xuzhen;Yang, Aiting;Das, Sukanta;Athavale, Dipti;Nieto, Natalia;You, Hong
- 通讯作者:You, Hong
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Natalia Nieto其他文献
Natalia Nieto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Natalia Nieto', 18)}}的其他基金
Protective role of OPN-High macrophages in NASH
OPN-High 巨噬细胞在 NASH 中的保护作用
- 批准号:
10752928 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Pathogenic role of a protein complex of liver origin as regulator of a proinflammatory program that drives hepatic and intestinal injury in alcoholic liver disease
肝脏来源的蛋白质复合物作为促炎程序的调节剂的致病作用,该程序驱动酒精性肝病中的肝脏和肠道损伤
- 批准号:
10358521 - 财政年份:2021
- 资助金额:
-- - 项目类别:
High-mobility group box-1 and alcoholic liver disease
高迁移率族box-1与酒精性肝病
- 批准号:
10197739 - 财政年份:2018
- 资助金额:
-- - 项目类别:
High-mobility group box-1 and alcoholic liver disease
高迁移率族box-1与酒精性肝病
- 批准号:
10451824 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
- 批准号:
9025179 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
- 批准号:
9088188 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
- 批准号:
8549929 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
- 批准号:
8693890 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
牛奶骨桥蛋白,酒精性肝炎的营养治疗干预措施
- 批准号:
8428356 - 财政年份:2012
- 资助金额:
-- - 项目类别:
相似海外基金
The role of matrix-bound microvesicles in alcohol-related liver disease
基质结合微泡在酒精相关性肝病中的作用
- 批准号:
10582800 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development and Testing of an Integrated Care Coordination Intervention for Alcohol Use Disorder Recovery after Liver Transplantation
肝移植后酒精使用障碍康复综合护理协调干预措施的开发和测试
- 批准号:
10723316 - 财政年份:2023
- 资助金额:
-- - 项目类别:
An innovative non-thiazolidinedione pan-PPAR agonist therapeutic for Alcoholic Hepatitis
一种创新的非噻唑烷二酮类泛 PPAR 激动剂,用于治疗酒精性肝炎
- 批准号:
10482468 - 财政年份:2022
- 资助金额:
-- - 项目类别: